News Archive - School of Medicine

Current Screening Methods Miss Worrisome Number of Persons with Mild Cognitive Impairment

In a paper published in the current Journal of Alzheimer’s Disease, researchers at University of California San Diego School of Medicine and Veterans Affairs San Diego Healthcare System say existing screening tools for mild cognitive impairment (MCI) result in a false-negative error rate of more than 7 percent. These persons are misclassified as not having MCI based on standard screening instruments but actually do have MCI when more extensive testing is conducted.

CIRM Grants May Fund the Next Great Stem Cell Achievement

All scientific achievement begins with an idea. Yesterday, three researchers at University of California San Diego School of Medicine were awarded funding by the Independent Citizens Oversight Committee of the California Institute for Regenerative Medicine (CIRM) to pursue budding ideas that might eventually impact the field of human stem cell research.

New International Initiative Will Focus on Immunology Research and Treatments

Immunology – and the idea that many diseases can best be addressed by boosting the body’s own immune response – is one of the hottest areas in medical research and clinical treatment. University of California San Diego School of Medicine and Chiba University School of Medicine in Japan have announced a new collaborative research center to investigate the most promising aspects of immunology, especially the area of mucosal immunology, and to speed development of clinical applications.

High Levels of Protein p62 Predict Liver Cancer Recurrence

Researchers at University of California San Diego School of Medicine and Sanford Burnham Prebys Medical Discovery Institute have discovered that high levels of the protein p62 in human liver samples are strongly associated with cancer recurrence and reduced patient survival. In mice, they also found that p62 is required for liver cancer to form.

UC San Diego Joins IBM World Community Grid’s Search for Zika Treatment

IBM's World Community Grid and scientists from Brazil, the Skaggs School of Pharmacy and Pharmaceutical Sciences at University of California San Diego, and Rutgers New Jersey Medical School have launched OpenZika, a project to find drug candidates to treat Zika, a fast spreading virus that the World Health Organization has declared a global public health emergency.

Blocking Known Cancer Driver Unexpectedly Reveals a New Tumor-Promoting Pathway

While investigating a potential therapeutic target for the ERK1 and 2 pathway, a widely expressed signaling molecule known to drive cancer growth in one third of patients with colorectal cancer, University of California San Diego School of Medicine researchers found that an alternative pathway immediately emerges when ERK1/2 is halted, thus allowing tumor cell proliferation to continue.

Immunization with Bacteria Promotes Stress Resilience, Coping Behaviors in Mice

Injections of the soil bacterium Mycobacterium vaccae promote stress resilience and improve coping behaviors in mice, according to a new study led by researchers at University of California San Diego School of Medicine and University of Colorado Boulder. The researchers also found that

UC San Diego to Participate in White House’s National Microbiome Initiative

On May 13, the White House Office of Science and Technology Policy (OSTP) announced a new National Microbiome Initiative, a coordinated effort to better understand microbiomes and to develop tools to protect and restore healthy microbiome function. OSTP is launching the initiative with a combined federal agency investment of more than $121 million. The University of California San Diego is a key participant in this effort, investing $12 million in its own microbiome research efforts.

Diabetes Drug Found No Better Than Placebo at Treating NAFLD

A diabetes medication described in some studies as an effective treatment for nonalcoholic fatty liver disease (NAFLD) works no better than a placebo, report researchers at University of California San Diego School of Medicine, after conducting the first randomized, double-blind, controlled clinical trial of sitagliptin, an oral antihyperglycemic marketed by Merck & Co. under the name Januvia.

Study Arms Sheriff’s Deputies with Nasal Spray for Drug Overdose Victims

Drug-related overdoses are the leading cause of injury-related deaths in the United States, surpassing motor vehicle accidents at 44,000 fatalities annually. In response, researchers at University of California San Diego School of Medicine have partnered with the San Diego County Sheriff’s Department to implement and study a program that requires all deputies carry and be trained to use a life-saving drug in the event of a discovered overdose and then refer victims to a treatment center once they are revived.